4.2.1.1
EUROPE AI ACT ACCELERATING DEMAND FOR COMPLIANT RADIOLOGY SOLUTIONS
4.2.1.2
EUROPE HEALTH DATA SPACE (EHDS) BOOSTING ACCESS TO STRUCTURED CROSS-BORDER IMAGING DATA
4.2.1.3
EUROPE FUNDING PROGRAMS SUPPORTING HEALTHCARE AI SCALE-UP
4.2.1.4
NATIONAL EHR/IMAGING DIGITIZATION PROGRAMS DRIVING PILOT DEPLOYMENTS IN PUBLIC SYSTEMS
4.2.1.5
OPERATIONAL PRESSURE FROM IMAGING BACKLOGS AND RADIOLOGIST CAPACITY GAPS
4.2.2.1
COMPLEX EUROPEAN REGULATIONS INCREASING AI CERTIFICATION BURDENS
4.2.2.2
FRAGMENTED NATIONAL INTERPRETATIONS OF GDPR AND CONSENT LIMITING POOLED TRAINING DATASETS
4.2.3.1
EHDS-ENABLED PAN-EU VALIDATION STUDIES AND REGULATORY EVIDENCE GENERATION
4.2.3.2
PROCUREMENT SCHEMES FAVORING COMPLIANT AI VENDORS
4.2.3.3
RISING DEMAND FOR PRIVACY-PRESERVING AI TECHNOLOGIES
4.2.3.4
CROSS-BORDER IMAGING COLLABORATIONS EXPANDING TRAINING DATASETS
4.2.4.1
REGULATORY/LEGAL UNCERTAINTY ABOUT LIABILITY AND CLINICAL ACCOUNTABILITY ACROSS MEMBER STATES
4.2.4.2
SLOW PUBLIC PROCUREMENT CYCLES AND LIMITED SCALE-UP CAPITAL FOR EUROPEAN MED-AI STARTUPS
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN HEALTHCARE IT INDUSTRY
5.5.1
INDICATIVE PRICE FOR EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE SOLUTIONS, BY KEY PLAYER (2024)
5.5.2
INDICATIVE PRICE FOR EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE SOLUTIONS, BY COUNTRY (2024)
5.6
KEY CONFERENCES & EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8
INVESTMENT & FUNDING SCENARIO
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
7.1
REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY OFFERING (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
9.3
NICHE/POINT SOLUTIONS
10
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY FUNCTION (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
10.2
DIAGNOSIS & EARLY DETECTION
10.2.3
DIAGNOSTIC IMAGING
10.2.4
RISK ASSESSMENT & PATIENT STRATIFICATION
10.2.5
DRUG ALLERGY ALERTING
10.3
TREATMENT PLANNING & PERSONALIZATION
10.3.1
PERSONALIZED TREATMENT PLANNING
10.3.1.1
PRECISION MEDICINE & GENOMIC ANALYSIS
10.3.1.2
PREDICTIVE MODELS FOR TREATMENT RESPONSE
10.3.1.3
TREATMENT RECOMMENDATION SYSTEMS
10.3.2
PHARMACOLOGICAL THERAPY
10.3.2.1
DRUG RESPONSE PREDICTION
10.3.2.2
DOSING & ADMINISTRATION
10.3.2.3
OTHER PHARMACOLOGICAL THERAPIES
10.3.3.1
PREOPERATIVE IMAGING & 3D MODELING
10.3.3.2
INTRAOPERATIVE GUIDANCE & ROBOTICS
10.3.3.3
POSTOPERATIVE ANALYSIS & RECOVERY
10.3.4.1
MOTION SYNCHRONIZATION & AUTO CONTOURING
10.3.4.2
REAL-TIME ADAPTIVE TREATMENT DELIVERY
10.3.4.3
RESPONSE ASSESSMENT & QUALITY ASSURANCE
10.3.4.4
OTHER RADIATION THERAPIES
10.3.5
BEHAVIORAL & PSCYCHOTHERAPY THERAPY
10.3.5.1
VIRTUAL COUNSELING & CHATBOTS
10.3.5.2
PROGRESS MONITORING & FEEDBACK
10.3.5.3
FOLLOW-UP & LONG-TERM SUPPORT
10.3.6.1
REAL-TIME PATIENT DATA MONITORING (IMAGING SCANS, BLOOD BIOMARKERS, VITALS)
10.3.6.2
RESPONSE & SIDE-EFFECT PREDICTION
10.3.6.3
RELAPSE PREDICTION & LONG-TERM MANAGEMENT
10.4
PATIENT ENGAGEMENT & REMOTE MONITORING
10.4.1
SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
10.4.2
TELEHEALTH & REMOTE PATIENT MONITORING
10.4.3
HEALTHCARE ASSISTANCE ROBOTS
10.4.4
MEDICATION REMINDERS
10.4.5
PATIENT EDUCATION & EMPOWERMENT
10.4.6
OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS
10.5
POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
10.5.1
RECURRENCE MONITORING
10.5.2
LONG-TERM OUTCOME PREDICTION
10.5.3
MENTAL HEALTH & SUPPORT SYSTEMS
10.6.2
MEDICATION MANAGEMENT
10.6.3
PHARMACY AUDIT & ANALYSIS
10.6.4
OTHER PHARMACY MANAGEMENT FUNCTIONS
10.7
DATA MANAGEMENT & ANALYTICS
10.8.1
PATIENT REGISTRATION & SCHEDULING
10.8.2
PATIENT ELIGIBILITY & AUTHORIZATION
10.8.3
BILLING & CLAIMS MANAGEMENT
10.8.4
WORKFORCE MANAGEMENT
10.8.5
SUPPLY CHAIN & INVENTORY MANAGEMENT
10.8.6
COMPLIANCE & DOCUMENTATION
10.8.7
HEALTHCARE WORKFLOW MANAGEMENT
10.8.9
CUSTOMER RELATIONSHIP MANAGEMENT
10.8.10
FRAUD DETECTION & RISK MANAGEMENT
10.8.12
OTHER ADMINISTRATIVE FUNCTIONS
11
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY APPLICATION (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
11.2
CLINICAL APPLICATIONS
11.3
NON-CLINICAL APPLICATIONS
12
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY DEPLOYMENT (USD MILLION) MODEL (MARKET SIZE & FORECAST TO 2030)
13
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY TOOL (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
13.2.1.1
CONVOLUTIONAL NEURAL NETWORKS (CNN)
13.2.1.2
RECURRENT NEURAL NETWORKS (RNN)
13.2.1.3
GENERATIVE ADVERSARIAL NETWORKS (GAN)
13.2.1.4
GRAPH NEURAL NETWORKS (GNN)
13.2.1.5
OTHER DEEP LEARNING TOOLS
13.2.2
SUPERVISED LEARNING
13.2.3
REINFORCEMENT LEARNING
13.2.4
UNSUPERVISED LEARNING
13.2.5
OTHER MACHINE LEARNING TOOLS
13.3
NATURAL LANGUAGE PROCESSING
13.3.1
SENTIMENT ANALYSIS
13.3.2
PATTERN & IMAGE RECOGNITION
13.3.4
CLASSIFICATION & CATEGORIZATION
13.3.6
SPEECH RECOGNITION
13.4
CONTEXT-AWARE COMPUTING
14
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY END USER (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
14.2
HEALTHCARE PROVIDERS
14.2.1
HOSPITALS & CLINICS
14.2.2
AMBULATORY CARE CENTERS
14.2.3
HOME HEALTHCARE AGENCIES & ASSISTED LIVING FACILITIES
14.2.4
DIAGNOSTIC & IMAGING CENTERS
14.2.6
OTHERS HEALTHCARE PROVIDERS
15
EUROPE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET, BY COUNTRY (USD MILLION) (MARKET SIZE & FORECAST TO 2030)
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
16.3
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
16.4
REVENUE ANALYSIS, 2020–2024
16.5
MARKET SHARE ANALYSIS,
16.6
BRAND/SOFTWARE COMPARISON
16.7
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.7.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.7.5.1
COMPANY FOOTPRINT
16.7.5.2
OFFERING FOOTPRINT
16.7.5.3
FUNCTION FOOTPRINT
16.7.5.4
APPLICATION FOOTPRINT
16.7.5.5
DEPLOYMENT FOOTPRINT
16.7.5.7
END-USER FOOTPRINT
16.8
COMPANY EVAULATION MATRIX: STARTUPS/SMES,
16.8.1
PROGRESSIVE COMPANIES
16.8.3
RESPONSIVE COMPANIES
16.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
16.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
16.9
COMPANY VALUATION & FINANCIAL METRICS
16.10
COMPETITIVE SCENARIO
16.10.1
PRODUCT LAUNCHES & UPGRADES
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET LANDSCAPE
17.2.1
KONINKLIJKE PHILIPS N.V.
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
17.2.2
MICROSOFT CORPORATION
17.2.3
SIEMENS HEALTHINEERS AG
17.2.4
NVIDIA CORPORATION
17.2.5
EPIC SYSTEMS CORPORATION
17.2.12
JOHNSON & JOHNSON
17.2.13
AMAZON WEB SERVICES, INC.
17.3.3
ULTROMICS LIMITED.
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.1.2.1
KEY DATA FROM PRIMARY SOURCES
18.1.2.2
KEY PRIMARY PARTICIPANTS
18.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.4
KEY INDUSTRY INSIGHTS
18.2
MARKET SIZE ESTIMATION
18.2.1
BOTTOM-UP APPROACH
18.2.3
BASE NUMBER CALCULATION
18.3
MARKET FORECAST APPROACH
18.6
RESEARCH ASSUMPTIONS
18.7
RESEARCH LIMITATIONS & RISK ASSESSMENT
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Europe Artificial Intelligence (AI) in Healthcare Market